Abstract illustration of inflamed skin folds, representing mucosal and intertriginous erosive dermatitis.

Beyond NME: Understanding Mucosal and Intertriginous Erosive Dermatitis

"Is Necrolytic Migratory Erythema a Misnomer? Exploring a More Accurate Diagnosis for Glucagonoma-Related Skin Conditions"


In dermatology, clarity in naming conditions is crucial for accurate diagnosis and effective treatment. However, some long-standing names can be misleading, potentially causing delays in proper care. One such case is necrolytic migratory erythema (NME), a skin condition strongly associated with glucagonoma, a rare tumor of the pancreas.

Traditional understanding suggests NME is a distinct entity directly caused by glucagonoma. However, recent research and clinical observations propose that the term 'necrolytic migratory erythema' might be a misnomer. The argument is that it does not fully capture the unique characteristics and locations of the skin lesions, potentially leading to delayed or misdirected diagnoses.

This article explores why some experts advocate for a more descriptive and accurate term: mucosal and intertriginous erosive dermatitis. We will delve into the defining features of this condition, its connection to glucagonoma, and why a shift in terminology could lead to earlier detection and better outcomes for affected individuals. Understanding the nuances of this condition is essential for healthcare professionals and anyone seeking clarity on glucagonoma-related skin manifestations.

AI Search Multiple angles on this topic

Consumer Deodorant Testing and Product Selection

The provided sources do not report prevalence or clinical outcomes for mucosal or intertriginous erosive dermatitis. The New York Times Wirecutter reports evaluating 45 deodorants, narrowing them to 39 for colleague testing, and selecting 20 after a three-month process. Other sources distinguish deodorants from antiperspirants and describe selection criteria such as ingredients, odor control, residue, and feel, but they do not establish dermatologic statistics.

Evidence Limitations

No source material was provided for this subsection. As a result, the standard clinical approach, accepted diagnostic methods, and their limitations cannot be described reliably here. Any detailed account would require dedicated dermatology or clinical sources.

Historical Evidence Gap

No source material was provided for this subsection. The supplied information therefore does not support claims about historical milestones or foundational discoveries related to mucosal and intertriginous erosive dermatitis. A historical account would require sources specifically addressing the condition.

Why 'Necrolytic Migratory Erythema' May Be Misleading?

Abstract illustration of inflamed skin folds, representing mucosal and intertriginous erosive dermatitis.

The term 'necrolytic migratory erythema' highlights two key features: necrolysis (skin cell death) and migration (the lesions moving or spreading). While these characteristics can be present, they don't always accurately represent the most consistent and prominent aspects of the skin condition associated with glucagonoma. Here's why:

The term "Necrolytic Migratory Erythema (NME)" is misleading for the following reasons:

  • Not Always Migratory: The lesions don't always 'migrate' in the classic sense of rapid movement across the skin. Instead, they often appear in specific areas and may persist or slowly expand over time.
  • Necrolysis Is Variable: While skin cell death (necrolysis) can occur, it's not always the dominant or most striking feature upon microscopic examination (histology). Other changes, like inflammation and skin thickening, might be more prominent.
  • Location Matters: The name doesn't emphasize the crucial predilection for mucosal surfaces (like the mouth and genitals) and intertriginous areas (skin folds). These locations are highly characteristic and should be a key diagnostic clue.
AI Search Multiple angles on this topic

Unrelated Microsoft Updates

The listed sources concern Microsoft Edge updates, Microsoft Support, Hotmail sign-in security, and Microsoft 365 Copilot. They describe browser maintenance, account verification, customer support, and workplace software, not research or reviews of erosive dermatitis. Accordingly, they provide no valid basis for conclusions about current dermatologic evidence.

Technology Deprecation Example

The sole source reports an update concerning the deprecation of Exchange Online EWS. This material addresses a software interface's changing support status rather than arguments, treatment failures, or diagnostic limitations in erosive dermatitis. It therefore cannot substantiate a dermatologic counterargument.

Insufficient Comparative Evidence

No source material was provided for this subsection. The available information does not support a comparison of mucosal and intertriginous erosive dermatitis with other dermatologic conditions. Such a comparison would require condition-specific clinical evidence.

By overemphasizing less consistent features and neglecting key locations, the term 'necrolytic migratory erythema' can inadvertently lead clinicians to consider other conditions first, delaying the recognition of glucagonoma as the underlying cause.

The Case for Change: A More Accurate Name

Given the limitations of the traditional name, experts propose 'mucosal and intertriginous erosive dermatitis' as a more accurate descriptor. This term emphasizes the key features that are most consistently observed in glucagonoma-related skin conditions: involvement of mucosal surfaces, occurrence in skin folds, and the presence of erosion and inflammation. By focusing on these defining characteristics, the hope is to raise awareness among clinicians and improve early detection rates.

AI Search Multiple angles on this topic

Unrelated Outer Banks Content

The supplied sources consist of an Outer Banks member login page and two cocktail recipes. One recipe lists bourbon whiskey, triple sec, maraschino liqueur, lemon juice, and orange bitters; the other lists lemon vodka, pink grapefruit juice, white cranberry juice, and lime slices. None provides expert commentary or evidence concerning erosive dermatitis.

Retail Technology Outlook

The listed sources describe Lightspeed retail and commerce software, including customizable business tools. Lightspeed DMS highlights streamlined service workflows, real-time inventory tracking, and communication between sales and service departments. These projected capabilities concern commerce operations and do not establish future directions for dermatology research.

Sports Rivalry Context

The provided sources discuss the Lakers-Suns rivalry, Phoenix Suns scheduling, player updates, and a 2026 game result. They identify a longstanding professional sports rivalry involving Arizona and Los Angeles and report that LeBron James led the Lakers to a victory on April 11, 2026. This material does not address systemic challenges associated with erosive dermatitis.

Evidence Not Provided

No source material was provided for this subsection. The supplied sources therefore do not support claims about patients' experiences, quality of life, or real-world effects of mucosal and intertriginous erosive dermatitis. Patient-focused conclusions would require relevant clinical or lived-experience sources.

A literature review of glucagonoma-associated skin findings

Durationpast 30 years[1]
Main outcomeDermatologic and histologic findings of NME in association with glucagonoma[1]
Times cited3[1]

How the review fits with clinical reports

Later cited material reported survival estimates and the resolution of a rash during nutritional support in an individual case. Neither observation tests the naming proposal; another report cautions that skin lesions do not always resolve with nutrient supplementation.[2] [3] [4]

What remains unresolved about the eruption

  • How often does NME occur outside glucagonoma, given reports linking it to inflammatory, liver, and nutritional or metabolic conditions?[5]
  • What mechanisms connect glucagon levels with skin-lesion changes, given reports that glucagon is not necessarily the direct cause but its normalization is associated with resolution?[4]
  • How consistently do skin lesions track metabolic or nutrient changes, given reports that some patients do not show those changes or lesion resolution after supplementation?[4]

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.2310/7750.2011.10134, Alternate LINK

Title: Is Necrolytic Migratory Erythema Due To Glucagonoma A Misnomer? A More Apt Name Might Be Mucosal And Intertriginous Erosive Dermatitis

Subject: Dermatology

Journal: Journal of Cutaneous Medicine and Surgery

Publisher: SAGE Publications

Authors: Parbeer Grewal, Thomas G. Salopek

Published: 2012-03-01

Everything You Need To Know

1

What is Necrolytic Migratory Erythema (NME), and why is it considered a potentially misleading term in dermatology?

Necrolytic Migratory Erythema (NME) is a skin condition traditionally associated with glucagonoma, a rare pancreatic tumor. The term is considered misleading because it emphasizes necrolysis (skin cell death) and migration of lesions, which are not always the most prominent or consistent features. The lesions do not always migrate rapidly, necrolysis isn't always the dominant histological feature, and the term neglects the characteristic involvement of mucosal surfaces and intertriginous areas, potentially delaying accurate diagnosis.

2

Why is 'mucosal and intertriginous erosive dermatitis' suggested as a more accurate term than 'necrolytic migratory erythema'?

'Mucosal and intertriginous erosive dermatitis' is proposed as a more accurate term because it highlights the key, consistent features of the skin condition associated with glucagonoma. It emphasizes the involvement of mucosal surfaces (like the mouth and genitals), occurrence in skin folds (intertriginous areas), and the presence of erosion and inflammation. This focus aims to improve early detection by drawing attention to the most reliable clinical signs.

3

How does the location of skin lesions play a critical role in diagnosing glucagonoma-related skin conditions?

The location of skin lesions is a crucial diagnostic clue because glucagonoma-related skin conditions frequently manifest on mucosal surfaces and in intertriginous areas. The traditional term 'necrolytic migratory erythema' doesn't emphasize these locations, which can lead clinicians to overlook glucagonoma as a potential underlying cause. Recognizing the predilection for mucosal and intertriginous areas can prompt earlier investigation for glucagonoma.

4

What are the potential implications of misdiagnosing or delaying the diagnosis of glucagonoma-related skin conditions due to the use of the term 'necrolytic migratory erythema'?

Misdiagnosing or delaying the diagnosis of glucagonoma-related skin conditions, because of the term 'necrolytic migratory erythema', can have significant implications. Since the skin condition is often a manifestation of an underlying glucagonoma, a delay in diagnosis can postpone treatment of the tumor itself. This delay can lead to disease progression, increased morbidity, and potentially decreased survival rates. Earlier and more accurate diagnosis is essential for timely intervention and improved patient outcomes.

5

Beyond the name, what other factors contribute to the challenges in diagnosing skin conditions related to glucagonoma, and what advancements are being made to address these challenges?

Besides the misleading name 'necrolytic migratory erythema', challenges in diagnosing skin conditions related to glucagonoma stem from the rarity of glucagonoma itself and the variability in lesion presentation. The absence of rapid migration, variable necrolysis, and unfamiliarity with the condition can cause diagnostic delays. Advancements include increased awareness among dermatologists and endocrinologists about the importance of considering mucosal and intertriginous involvement, promoting thorough skin examinations in patients with suspected glucagonoma, and developing diagnostic algorithms that prioritize key clinical features to improve recognition and prompt further investigation.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.